RBC Capital analyst Gregory Renza reiterated a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.83.
Renza covers the Healthcare sector, focusing on stocks such as Amgen, Exelixis, and Viridian Therapeutics. According to TipRanks, Renza has an average return of 13.7% and a 45.51% success rate on recommended stocks.
In addition to RBC Capital, Exelixis also received a Buy from TD Cowen’s Yaron Werber in a report issued today. However, on the same day, Goldman Sachs maintained a Sell rating on Exelixis (NASDAQ: EXEL).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $24.34 and a one-year low of $16.15. Currently, Exelixis has an average volume of 2.03M.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis (EXEL) Company Description:
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Read More on EXEL:
- EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exelixis price target raised to $25 from $24 at Barclays
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Exelixis announces results of study evaluating cabozantinib in mCRPC treatment
- Bristol Myers, Exelixis announce four-year results from Opdivo-Cabometyx trial
